Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Pastan Website

Ira Pastan, M.D.

Selected Publications

1)  Hassan R, Miller AC, Sharon E, Thomas A, Reynolds JC, Ling A, Kreitman RJ, Miettinen MM, Steinberg SM, Fowler DH, Pastan I.
Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression.
Sci Transl Med. 5: 208ra147, 2013.
2)  Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, Fitzgerald DJ, Lechleider R, Pastan I.
Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia.
J. Clin. Oncol. 30: 1822-8, 2012.
3)  Chaudhary VK, Queen C, Junghans RP, Waldmann TA, FitzGerald DJ, Pastan I.
A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin.
Nature. 339: 394-7, 1989.
4)  Chang K, Pastan I.
Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.
Proc. Natl. Acad. Sci. U.S.A. 93: 136-40, 1996.
5)  Liu W, Onda M, Kim C, Xiang L, Weldon JE, Lee B, Pastan I.
A recombinant immunotoxin engineered for increased stability by adding a disulfide bond has decreased immunogenicity.
Protein Eng. Des. Sel. 25: 1-6, 2012.
6)  Acs P, Bauer PO, Mayer B, Bera T, Macallister R, Mezey E, Pastan I.
A novel form of ciliopathy underlies hyperphagia and obesity in Ankrd26 knockout mice.
Brain Struct Funct. [Epub ahead of print], 2014.
7)  Liu XF, Xiang L, FitzGerald DJ, Pastan I.
Antitumor effects of immunotoxins are enhanced by lowering HCK or treatment with SRC kinase inhibitors.
Mol. Cancer Ther. 13: 82-9, 2014.
8)  Terrier B, Nagata S, Ise T, Rosenzwajg M, Pastan I, Klatzmann D, Saadoun D, Cacoub P.
CD21(-/low) marginal zone B cells highly express Fc receptor-like 5 protein and are killed by anti-Fc receptor-like 5 immunotoxins in hepatitis C virus-associated mixed cryoglobulinemia vasculitis.
Arthritis Rheumatol. 66: 433-43, 2014.
9)  Hollevoet K, Antignani A, Fitzgerald DJ, Pastan I.
Combining the antimesothelin immunotoxin SS1P with the BH3-mimetic ABT-737 induces cell death in SS1P-resistant pancreatic cancer cells.
J. Immunother. 37: 8-15, 2014.
10)  Wayne AS, Fitzgerald DJ, Kreitman RJ, Pastan I.
Immunotoxins for leukemia.
Blood. 123: 2470-7, 2014.
11)  Miyazaki Y, Shimizu A, Pastan I, Taguchi K, Naganuma E, Suzuki T, Hosoya T, Yokoo T, Saito A, Miyata T, Yamamoto M, Matsusaka T.
Keap1 inhibition attenuates glomerulosclerosis.
Nephrol. Dial. Transplant. 29: 783-91, 2014.
12)  Miyazaki Y, Shimizu A, Ichikawa I, Hosoya T, Pastan I, Matsusaka T.
Mice are unable to endogenously regenerate podocytes during the repair of immunotoxin-induced glomerular injury.
Nephrol. Dial. Transplant. 29: 1005-12, 2014.
13)  Matsusaka T, Niimura F, Pastan I, Shintani A, Nishiyama A, Ichikawa I.
Podocyte injury enhances filtration of liver-derived angiotensinogen and renal angiotensin II generation.
Kidney Int. 85: 1068-77, 2014.
14)  Mazor R, Eberle JA, Hu X, Vassall AN, Onda M, Beers R, Lee EC, Kreitman RJ, Lee B, Baker D, King C, Hassan R, Benhar I, Pastan I.
Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes.
Proc. Natl. Acad. Sci. U.S.A. [Epub ahead of print], 2014.
15)  Denton PW, Long JM, Wietgrefe SW, Sykes C, Spagnuolo RA, Snyder OD, Perkey K, Archin NM, Choudhary SK, Yang K, Hudgens MG, Pastan I, Haase AT, Kashuba AD, Berger EA, Margolis DM, Garcia JV.
Targeted cytotoxic therapy kills persisting HIV infected cells during ART.
PLoS Pathog. 10: e1003872, 2014.
16)  Sakamoto K, Ueno T, Kobayashi N, Hara S, Takashima Y, Pastan I, Matsusaka T, Nagata M.
The direction and role of phenotypic transition between podocytes and parietal epithelial cells in focal segmental glomerulosclerosis.
Am. J. Physiol. Renal Physiol. 306: F98-F104, 2014.
17)  Yamada S, Nakamura J, Asada M, Takase M, Matsusaka T, Iguchi T, Yamada R, Tanaka M, Higashi AY, Okuda T, Asada N, Fukatsu A, Kawachi H, Graf D, Muso E, Kita T, Kimura T, Pastan I, Economides AN, Yanagita M.
Twisted gastrulation, a BMP antagonist, exacerbates podocyte injury.
PLoS ONE. 9: e89135, 2014.
18)  Wei H, Bera TK, Wayne AS, Xiang L, Colantonio S, Chertov O, Pastan I.
A modified form of diphthamide causes immunotoxin resistance in a lymphoma cell line with a deletion of the WDR85 gene.
J. Biol. Chem. 288: 12305-12, 2013.
19)  Choi BD, Pastan I, Bigner DD, Sampson JH.
A novel bispecific antibody recruits T cells to eradicate tumors in the "immunologically privileged" central nervous system.
Oncoimmunology. 2: e23639, 2013.
20)  Weldon JE, Xiang L, Zhang J, Beers R, Walker DA, Onda M, Hassan R, Pastan I.
A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity.
Mol. Cancer Ther. 12: 48-57, 2013.
21)  Ueno T, Kobayashi N, Nakayama M, Takashima Y, Ohse T, Pastan I, Pippin JW, Shankland SJ, Uesugi N, Matsusaka T, Nagata M.
Aberrant Notch1-dependent effects on glomerular parietal epithelial cells promotes collapsing focal segmental glomerulosclerosis with progressive podocyte loss.
Kidney Int. 83: 1065-75, 2013.
22)  Piao H, Kuan CT, Chandramohan V, Keir ST, Pegram CN, Bao X, Månsson JE, Pastan IH, Bigner DD.
Affinity-matured recombinant immunotoxin targeting gangliosides 3"-isoLM1 and 3",6"-isoLD1 on malignant gliomas.
MAbs. 5: 748-62, 2013.
23)  Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, Dimitrov DS, Morgan RA, FitzGerald DJ, Barrett DM, Wayne AS, Mackall CL, Orentas RJ.
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.
Blood. 121: 1165-74, 2013.
24)  Molavi O, Xiong XB, Douglas D, Kneteman N, Nagata S, Pastan I, Chu Q, Lavasanifar A, Lai R.
Anti-CD30 antibody conjugated liposomal doxorubicin with significantly improved therapeutic efficacy against anaplastic large cell lymphoma.
Biomaterials. 34: 8718-25, 2013.
25)  Mattoo AR, Pastan I, Fitzgerald D.
Combination treatments with the PKC inhibitor, enzastaurin, enhance the cytotoxicity of the anti-mesothelin immunotoxin, SS1P.
PLoS ONE. 8: e75576, 2013.
26)  Chandramohan V, Bao X, Keir ST, Pegram CN, Szafranski SE, Piao H, Wikstrand CJ, McLendon RE, Kuan CT, Pastan IH, Bigner DD.
Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy.
Clin. Cancer Res. 19: 4717-27, 2013.
27)  Yamaguchi T, Danjo T, Pastan I, Hikida T, Nakanishi S.
Distinct roles of segregated transmission of the septo-habenular pathway in anxiety and fear.
Neuron. 78: 537-44, 2013.
28)  Huang YH, Terabe M, Pendleton CD, Stewart Khursigara D, Bera TK, Pastan I, Berzofsky JA.
Identification and enhancement of HLA-A2.1-restricted CTL epitopes in a new human cancer antigen-POTE.
PLoS ONE. 8: e64365, 2013.
29)  Hu X, Wei H, Xiang L, Chertov O, Wayne AS, Bera TK, Pastan I.
Methylation of the DPH1 promoter causes immunotoxin resistance in acute lymphoblastic leukemia cell line KOPN-8.
Leuk. Res. 37: 1551-6, 2013.
30)  Chandramohan V, Bao X, Kato Kaneko M, Kato Y, Keir ST, Szafranski SE, Kuan CT, Pastan IH, Bigner DD.
Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors.
Int. J. Cancer. 132: 2339-48, 2013.
31)  Choi BD, Kuan CT, Cai M, Archer GE, Mitchell DA, Gedeon PC, Sanchez-Perez L, Pastan I, Bigner DD, Sampson JH.
Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma.
Proc. Natl. Acad. Sci. U.S.A. 110: 270-5, 2013.
32)  Liu XF, FitzGerald DJ, Pastan I.
The insulin receptor negatively regulates the action of Pseudomonas toxin-based immunotoxins and native Pseudomonas toxin.
Cancer Res. 73: 2281-8, 2013.
Click Here to View Collapsed Bibliography.

This page was last updated on 5/14/2014.